72 HAMMERSMITH ROAD, LONDON, X0
Investor Presentation
2026 AGM Results - Silence Therapeutics plc Shareholder Votes
Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera
Silence Therapeutics Enters Open Market Sale Agreement with Jefferies
Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Amended material disclosure
Q1
FY 2025
Q3
Q2
Amended Annual Report
FY 2023
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Definitive Proxy Statement
PRE 14A
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report